Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Nóra, Breza"'
Autor:
Péter Bánhegyi, László Őrfi, Zoltán Horváth, Csaba Szántai-Kis, Mária Balogh, Bálint Szokol, Zsófia Czudor, Eszter Illyés, Judit Dobos, Márk Fábián, Nóra Breza, Sándor Boros, Anna Sipos, Péter Markó
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 28:769-773
Cyclin-dependent kinases (CDKs) and Polo-like kinases (PLKs) play key role in the regulation of the cell cycle. The aim of our study was originally the further development of our recently discovered polo-like kinase 1 (PLK1) inhibitors. A series of n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47c0139cad5407f466b20ae41d91c700
https://doi.org/10.1016/j.bmcl.2018.01.002
https://doi.org/10.1016/j.bmcl.2018.01.002
Autor:
Ervinna Pang, Y. R. Ng, Zoltán Horváth, Lilian Zsákai, Nóra Breza, János Pató, Gábor Németh, Csaba Szántai-Kis, Axel Ullrich, István Szabadkai, György Kéri, Ferenc Baska, Laszlo Orfi, Boon Tin Chua, Han Kiat Ho, Zoltan Greff, Bálint Szokol
Publikováno v:
Current Medicinal Chemistry. 20:1203-1217
Fibroblast growth factor receptor-4 (FGFR4) is a tyrosine kinase with a range of important physiological functions. However, it is also frequently mutated in various cancers and is now generating significant interest as a potential therapeutic target
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c0267251a1b2df0b9bd230a20df03e9
https://doi.org/10.2174/0929867311320100001
https://doi.org/10.2174/0929867311320100001
Autor:
György Kéri, Zoltán Greff, Doris Hafenbradl, György Mészáros, M. Ko, Laszlo Orfi, Yossef Av-Gay, Csaba Szántai-Kis, Róbert Gábor Kiss, János Pató, S. Perozzi, Bert Klebl, R. Szekely, Péter Bánhegyi, Zoltán Horváth, Silvia Garavaglia, D. Eros, Gabor Borbely, Gábor Németh, Zoltán Varga, Menico Rizzi, Jenö Marosfalvi, Nóra Breza, Bálint Hegymegi-Barakonyi
Publikováno v:
Current Medicinal Chemistry. 15:2760-2770
Tuberculosis causes nearly two million deaths per year world-wide. In addition multidrug-resistant mycobacterial strains rapidly emerge so novel therapeutic approaches are needed. Recently, several promising mycobacterial target molecules were identi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5509b4be3f118bff74fae83b3fd6f53
https://doi.org/10.2174/092986708786242886
https://doi.org/10.2174/092986708786242886
Autor:
Kiss Robert, Nóra Breza, István Peták, Laszlo Orfi, Richard Schwab, Edit Várkondi, Ferenc Pinter, György Kéri
Publikováno v:
Journal of Receptors and Signal Transduction. 28:295-306
Gefitinib and erlotinib are potent EGFR tyrosine kinase inhibitors (potentially) useful for the treatment of non-small-cell lung cancer (NSCLC). Clinical responses, however, in NSCLC patients have been linked to the presence of certain activating mut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::393f6d1dfe7fbe86f353737b3cdd04b1
https://doi.org/10.1080/10799890802084671
https://doi.org/10.1080/10799890802084671
Autor:
Gabor Borbely, János Pató, Péter Bánhegyi, Nóra Breza, Bálint Hegymegi-Barakonyi, Edit Várkondi, Laszlo Orfi, István Peták, György Kéri
Publikováno v:
Journal of Receptors and Signal Transduction. 28:361-373
The development of selective protein kinase inhibitors has become an important area of drug discovery for the treatment of different diseases. We report the synthesis and characterization of a series of novel quinazoline derivatives against three the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6188eac2eac81cd72b292673f9230aa9
https://doi.org/10.1080/10799890802242618
https://doi.org/10.1080/10799890802242618
Autor:
László, Kékesi, Anna, Sipos, Gábor, Németh, András, Dancsó, Eszter, Illyés, Sándor, Boros, Nóra, Breza, Zoltán, Nemes, Bálint, Hegymegi-Barakonyi, János, Pató, Zoltán, Greff, György, Kéri, László, Őrfi
Publikováno v:
Acta pharmaceutica Hungarica. 84(3)
The EGFR inhibitor erlotinib possesses high anti-tumor effect but despite the good clinical responses in most of the cases recrudescence occures. This can be attributed to a secondary, acquired mutation causing resistance to tyrosine kinase inhibitor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c3eb5156d7bece62376b603558b68313
https://pubmed.ncbi.nlm.nih.gov/25470976
https://pubmed.ncbi.nlm.nih.gov/25470976
Autor:
Ferenc, Baska, Edina Rita, Székely, Csaba, Szántai-Kis, Péter, Bánhegyi, Bálint, Hegymegi-Barakonyi, Gábor, Németh, Nóra, Breza, Lilian, Zsákai, Zoltán, Greff, János, Pató, György, Kéri, Lászlo, Orfi
Publikováno v:
Acta pharmaceutica Hungarica. 83(3)
Tuberculosis is considered to be one of the major health problem not only in the less developed countries but in the economically developed countries as well. Roughly one third of the world's population are infected with Mycobacterium tuberculosis an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::afe7359df097c1c437586c543101150b
https://pubmed.ncbi.nlm.nih.gov/24369587
https://pubmed.ncbi.nlm.nih.gov/24369587
Autor:
Ferenc Baska, György Kéri, László Hunyady, Zoltán Varga, Péter Markó, Nóra Breza, Monika Huszar, Zoltán Horváth, Tibor Vántus, László Buday, Laszlo Orfi, Gabor Borbely, István Szabadkai, Miklós Geiszt
Publikováno v:
Journal of medicinal chemistry. 53(18)
NOX enzymes are the major contributors in many oxidative damage related diseases. Unfortunately, at present no specific NOX inhibitor is available. Here, we describe the discovery and development of novel NOX4 inhibitors. Compound libraries were test
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92eae2ce06bb402d769ae0e4c8cc1040
https://pubmed.ncbi.nlm.nih.gov/20731357
https://pubmed.ncbi.nlm.nih.gov/20731357